CA25253X2077 - Common Stock
DIAMEDICA THERAPEUTICS INC
NASDAQ:DMAC (5/1/2024, 7:00:01 PM)
2.59
+0.06 (+2.37%)
DiaMedica Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. The company is headquartered in Minneapolis, Minnesota and currently employs 16 full-time employees. The company went IPO on 2008-01-04. The firm is focused on developing treatments for kidney diseases, such as acute ischemic stroke (AIS) and chronic kidney disease (CKD). The firm's lead product, DM199, is an active recombinant (synthetic) form of the human tissue kallikrein-1 (KLK1) protein for the treatment of AIS and CKD, including hypertensive nephrosclerosis (hypertension). KLK1 is a serine protease (protein) that plays a role in the regulation of diverse physiological processes, including blood flow, inflammation, fibrosis, oxidative stress, and neurogenesis, via a molecular mechanism that increases the production of nitric oxide and prostaglandin. The company has also identified a potential treatment for inflammatory diseases, DM300, which is in the early preclinical stage of development.
DIAMEDICA THERAPEUTICS INC
301 Carlson Parkway, Suite 210
Minneapolis MINNESOTA 55447
P: 17634965454
CEO: Rick Pauls
Employees: 16
Website: https://www.diamedica.com/
DMAC stock results show that DiaMedica Therapeutics met analyst estimates for earnings per share the fourth quarter of 2023.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips DiaMedica Therapeutics (NASDAQ:DMAC) just reported results for the fourth quart...
DiaMedica Therapeutics appoints Lorianne Masuoka as its chief medical officer, bringing over 20 years of experience in the pharmaceutical industry.
Here you can normally see the latest stock twits on DMAC, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: